Decreased Mortality in a Large Cohort of COVID-19 Patients


Coronavirus disease 2019 (COVID-19) convalescent plasma has emerged as a promising therapy and has been granted Emergency Use Authorization by the US Food and Drug Administration for hospitalized COVID-19 patients. The American Journal of Pathology(AJP) recently reported results from an interim analysis of a propensity score-matched study suggesting that early treatment of COVID-19 patients with convalescent plasma containing high-titer anti-spike protein receptor-binding domain (RBD) IgG significantly decreases mortality. Check out the full story published by the American Journal of Pathology(AJP) right here.

0 comments